Paliperidone
- Generic Name
- Paliperidone
- Brand Names
- Invega, Invega Hafyera, Xeplion, Niapelf, Byannli (previously Paliperidone Janssen-Cilag International), Trevicta (previously Paliperidone Janssen), ERZOFRI
- Drug Type
- Small Molecule
- Chemical Formula
- C23H27FN4O3
- CAS Number
- 144598-75-4
- Unique Ingredient Identifier
- 838F01T721
- Background
Paliperidone is the primary active metabolite of risperidone. The mechanism of action is unknown but it is likely to act via a similar pathway to risperidone. It has been proposed that the drug's therapeutic activity in schizophrenia is mediated through a combination of central dopamine Type 2 (D2) and serotonin Type 2 (5HT2A) receptor antagonism. Paliperido...
- Indication
As an oral extended-release tablet and a once-monthly extended-release suspension for intramuscular injection, paliperidone is indicated for the treatment of adults and adolescents with schizophrenia and in the treatment of schizoaffective disorder in combination with antidepressants or mood stabilizers. Paliperidone is also available in both an every-three-...
- Associated Conditions
- Schizoaffective Disorders, Schizophrenia
- Associated Therapies
- -
Double Blinded, Placebo-Controlled Trial of Paliperidone Addition in SRI-Resistant Obsessive-Compulsive Disorder
- First Posted Date
- 2008-03-10
- Last Posted Date
- 2014-02-06
- Lead Sponsor
- University of South Florida
- Target Recruit Count
- 34
- Registration Number
- NCT00632229
- Locations
- 🇺🇸
University of South Florida, St. Petersburg, Florida, United States
🇺🇸University Hospital Outpatient Center, Psychiatry, Indianapolis, Indiana, United States
Invega (Paliperidone) for the Treatment of Mania in Children and Adolescents Ages 6-17 With Bipolar Disorder
- First Posted Date
- 2008-01-14
- Last Posted Date
- 2012-07-04
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 17
- Registration Number
- NCT00592358
- Locations
- 🇺🇸
Massachusetts General Hospital, Cambridge, Massachusetts, United States
An Efficacy and Safety Study of Paliperidone Extended-Release (ER) Tablets in Participants With Schizophrenia
- First Posted Date
- 2007-12-03
- Last Posted Date
- 2013-08-02
- Lead Sponsor
- Janssen-Cilag International NV
- Target Recruit Count
- 294
- Registration Number
- NCT00566631
An Open Label Multicentre Study to Determine the Dose Distribution of Paliperidone ER in Patients With Schizophrenia
- First Posted Date
- 2007-05-15
- Last Posted Date
- 2012-12-05
- Lead Sponsor
- Janssen-Cilag Pty Ltd
- Target Recruit Count
- 64
- Registration Number
- NCT00473434
Preventing Relapse in Schizophrenia: Oral Antipsychotics Compared To Injectables: Evaluating Efficacy
- First Posted Date
- 2006-05-29
- Last Posted Date
- 2018-07-10
- Lead Sponsor
- Northwell Health
- Target Recruit Count
- 357
- Registration Number
- NCT00330863
- Locations
- 🇺🇸
University of California, Los Angeles, Los Angeles, California, United States
🇺🇸Medical College of Georgia, Department of Psychiatry, Augusta, Georgia, United States
🇺🇸Harvard Medical School -- Dr. John C. Corrigan Community Mental Health Center, Fall River, Massachusetts, United States
An Exploratory Study on the Safety and Effectiveness of Paliperidone in Patients With Schizophrenia
- Conditions
- First Posted Date
- 2005-11-22
- Last Posted Date
- 2011-05-17
- Lead Sponsor
- Janssen Pharmaceutical K.K.
- Target Recruit Count
- 52
- Registration Number
- NCT00257023
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.